Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections

Rhea-AI Summary

Beyond Air (NASDAQ: XAIR) commented on a landmark independent review published Feb 2026 that synthesizes data from 27 studies on high‑dose inhaled nitric oxide (iNO) delivered well above the FDA‑approved 20 ppm. The review highlights multimodal antimicrobial activity, potential in pneumonia, NTM, bronchiolitis, COVID‑19, and a roadmap for future research.

Beyond Air noted the review reinforces momentum behind its clinical programs and could accelerate development of high‑dose iNO as a novel respiratory antimicrobial.

Positive

• 27 studies synthesized showing emerging clinical evidence
• Review highlights multimodal antimicrobial mechanisms of high‑dose iNO
• Company clinical programs reported promising signals in NTM, bronchiolitis, VCAP, COVID‑19

Negative

• High‑dose iNO exceeds the FDA‑approved 20 ppm, implying regulatory hurdles
• Available evidence derives largely from early‑phase studies, not definitive approvals

News Market Reaction – XAIR

-3.95%

8 alerts

-3.95% News Effect

-3.9% Trough in 6 hr 13 min

-$801K Valuation Impact

$19M Market Cap

0.6x Rel. Volume

On the day this news was published, XAIR declined 3.95%, reflecting a moderate negative market reaction. Argus tracked a trough of -3.9% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $801K from the company's valuation, bringing the market cap to $19M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Approved iNO dose: 20 ppm Studies reviewed: 27 studies

2 metrics

Approved iNO dose 20 ppm FDA-approved inhaled nitric oxide vasodilation dose cited for comparison

Studies reviewed 27 studies Clinical and mechanistic data across in-hospital and at-home settings

Market Reality Check

Price: $1.01 Vol: Volume 126,175 is light a...

low vol

$1.01 Last Close

Volume Volume 126,175 is light at 0.32x the 20-day average 389,535, suggesting limited pre-news positioning. low

Technical Shares at $1.09 are trading below the 200-day MA of $2.36 and 86.32% below the 52-week high, despite being 61.89% above the 52-week low.

Peers on Argus

Momentum data show 2 peers (e.g., INBS up 2.73%) moving up, but sector_momentum ...

2 Up

Momentum data show 2 peers (e.g., INBS up 2.73%) moving up, but sector_momentum is flagged as not a sector-wide move and XAIR’s own direction is not defined, pointing to stock-specific drivers.

Historical Context

5 past events · Latest: Feb 13 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 13	Earnings and update	Positive	+2.9%	Strong Q3 growth, narrower loss and reiterated revenue guidance.
Feb 04	Clinical data abstract	Positive	-5.2%	Selection to present Phase 1 UNO solid tumor data at AACR.
Jan 27	Investor conferences	Neutral	-7.5%	CEO participation in two early‑February healthcare investor conferences.
Jan 26	Earnings call notice	Neutral	-9.9%	Scheduling and access details for upcoming Q3 2026 earnings call.
Jan 14	Private placement	Negative	-14.2%	$5.0M at‑the‑market private placement with new shares and warrants.

Pattern Detected

Recent history shows pressure on the stock around neutral-to-positive corporate events, while financing and dilution-linked news have been met with pronounced declines.

Recent Company History

Over the past months, Beyond Air has mixed financial and strategic catalysts. Fiscal Q3 2026 earnings on Feb 13 showed strong 105% revenue growth to $2.2M and a modestly positive price reaction. Earlier in February, a Phase 1 UNO cancer abstract and conference participation news on Jan 27 both saw negative reactions. A $5.0M private placement on Jan 14 triggered a double‑digit decline. Today’s scientific review on high‑dose iNO fits into an ongoing narrative of building clinical validation around nitric oxide–based platforms.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2026-01-30

An effective S-3 shelf dated 2026-01-30 allows existing holders to resell 524,990 common shares plus additional warrant shares. Beyond Air would not receive proceeds from these resales but could receive cash upon warrant exercise, and total shares could rise from 10,529,344 to 17,865,990 if all warrant shares in this filing are issued.

Market Pulse Summary

This announcement centers on an independent review compiling data from 27 studies of high‑dose inhal...

Analysis

This announcement centers on an independent review compiling data from 27 studies of high‑dose inhaled nitric oxide as a broad‑spectrum antimicrobial for diverse respiratory infections. It reinforces Beyond Air’s focus on nitric‑oxide platforms while the stock trades well below its 200-day MA of $2.36 and 86.32% under its 52-week high. Investors may track future clinical trial readouts, regulatory milestones, and any additional use of the existing S-3 registration as key indicators of risk and progress.

Key Terms

inhaled nitric oxide, antimicrobial, bronchiolitis, nontuberculous mycobacteria, +4 more

8 terms

inhaled nitric oxide medical

"overview to date of high‑dose inhaled nitric oxide (iNO) delivered at concentrations..."

Inhaled nitric oxide is a hospital-delivered medical gas that, when breathed in, relaxes and widens the tiny blood vessels in the lungs so oxygen transfers into the bloodstream more easily — think of it as temporarily clearing traffic on a crowded lung highway. For investors, it matters because regulatory approvals, clinical trial results, safety profiles, and how readily hospitals adopt the gas and related delivery devices directly affect sales, reimbursement and the commercial outlook for companies developing or supplying it.

antimicrobial medical

"may function as a novel broad‑spectrum antimicrobial therapy for a wide range..."

Antimicrobial describes a substance or treatment that kills or stops the growth of microbes — germs such as bacteria, fungi, viruses or other tiny organisms. For investors, antimicrobials matter because they define markets for drugs, vaccines, medical devices and disinfectants, influence regulatory approval and hospital purchasing, and face risks from resistance that can shrink demand or require costly new development; think of them as products that protect against unwanted invaders.

bronchiolitis medical

"early‑phase clinical trials in pneumonia, COVID‑19, bronchiolitis, and nontuberculous..."

An infection of the small airways in the lungs, most often caused by a virus and usually seen in infants and young children; it makes those tiny air tubes swell and fill with mucus, like garden hoses narrowed by kinks and debris. It matters to investors because outbreaks drive demand for pediatric hospital beds, emergency care, tests, therapies and vaccines, affect healthcare costs and staffing, and can influence revenue and regulatory focus for companies in diagnostics, pharmaceuticals and hospital services.

nontuberculous mycobacteria medical

"trials in pneumonia, COVID‑19, bronchiolitis, and nontuberculous mycobacteria (NTM)..."

Nontuberculous mycobacteria are a group of environmental bacteria related to the organism that causes tuberculosis but that do not cause TB; think of them as distant cousins that can live in water, soil and building systems and sometimes infect people, especially the lungs. They matter to investors because infections are often long-lasting, hard to treat and require specialized drugs, diagnostics and hospital care, so rising cases or new treatment options can affect sales, regulatory risk and valuation for drugmakers, device companies and healthcare providers.

hospital‑acquired pneumonia medical

"emphasizing opportunities in hospital‑acquired pneumonia, ventilator‑associated pneumonia..."

An infection of the lungs that a patient develops while admitted to a hospital, typically 48 hours or more after being there, often caused by different germs than community illnesses. Investors care because it drives demand for hospital treatments, antibiotics, devices and longer stays, which affects healthcare costs, drug sales and hospital revenue—think of it as an unexpected repair bill that can change a provider’s or drug maker’s financial picture.

ventilator‑associated pneumonia medical

"opportunities in hospital‑acquired pneumonia, ventilator‑associated pneumonia, tuberculosis..."

An infection of the lungs that develops in patients who have been placed on a mechanical breathing machine in a hospital; germs can enter the airway around the tube and cause inflammation and fluid in the lungs. It matters to investors because it increases hospital stays, treatment costs and readmissions, can drive demand for antibiotics, diagnostics and safer devices, and can trigger regulatory scrutiny or liability—like a car engine getting contaminated while running and needing costly repairs.

post‑viral fibrosis medical

"ventilator‑associated pneumonia, tuberculosis, post‑viral fibrosis, and in immunocompromised..."

Post-viral fibrosis is scarring and stiffening of tissue—most commonly lung tissue—that can develop when healing after a viral infection goes wrong, leaving areas of the organ less flexible and less able to work. It matters to investors because it creates long-term medical needs and predictable revenue streams for drug makers, device manufacturers, diagnostics and healthcare providers, while raising potential costs for insurers and employers; think of it like a once-flexible fabric that has been permanently patched and no longer stretches.

immunocompromised medical

"tuberculosis, post‑viral fibrosis, and in immunocompromised patients, among others..."

A person who is immunocompromised has a weakened ability to fight infections because their body’s natural defense system is reduced or impaired, like a building with a compromised security system. For investors, this matters because treatments, vaccines, and medical products for immunocompromised patients can drive specialized drug demand, alter clinical trial design and regulatory pathways, and affect market size, pricing and long‑term revenue potential.

AI-generated analysis. Not financial advice.

GARDEN CITY, N.Y., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today commented on the publication of an independent review article providing the most comprehensive overview to date of high‑dose inhaled nitric oxide (iNO) delivered at concentrations well above the FDA‑approved 20 ppm, and presenting mounting evidence that high‑dose iNO may function as a novel broad‑spectrum antimicrobial therapy for a wide range of respiratory infections. Titled “The therapeutic potential of high‑dose inhaled nitric oxide for antimicrobial effects: a narrative review and future directions,” the article was published in Intensive Care Medicine Experimental (ICMx), a peer-reviewed, open-access journal of the European Society of Intensive Care Medicine, published by Springer Nature Switzerland AG.

The article reviews the emerging clinical evidence supporting the safe administration of iNO at concentrations far exceeding the traditional doses currently used for vasodilation. Its authors synthesized clinical and mechanistic data from 27 studies conducted in both in-hospital and at-home settings– including early‑phase clinical trials in pneumonia, COVID‑19, bronchiolitis, and nontuberculous mycobacteria (NTM) – to illustrate the breadth of ongoing research. The paper highlights the unique multimodal activity of high‑dose iNO, including direct microbial killing, biofilm disruption, antiviral effects, inflammation reduction, and enhanced mucociliary clearance. It also outlines a potential roadmap for future research, emphasizing opportunities in hospital‑acquired pneumonia, ventilator‑associated pneumonia, tuberculosis, post‑viral fibrosis, and in immunocompromised patients, among others – areas where new therapeutic tools are urgently needed.

“We are excited to see the scientific community increasingly recognize high‑dose iNO as a potential game‑changing antimicrobial platform for respiratory infections,” said Steve Lisi, Chief Executive Officer of Beyond Air. “A growing collection of studies shows that high‑dose iNO can address pathogens and clinical challenges that current therapies are unable to treat. This most recent article builds on the momentum of our own clinical programs that have demonstrated promising signals in NTM, bronchiolitis, community‑acquired pneumonia (VCAP), and COVID-19. We believe the publication of this article will serve as a catalyst for new scientific research and accelerate the clinical development of high‑dose iNO as a potential transformative treatment modality for pulmonary indications.”

About Beyond Air^®, Inc.
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM).

Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.

About LungFit *
Beyond Air's LungFit is a cylinder-free, phasic flow generator and delivery system designated as a medical device by the U.S. Food and Drug Administration (FDA). The ventilator-compatible version of the device can generate NO from ambient air on demand for delivery to the lungs at concentrations ranging from 1 ppm to 80 ppm. The LungFit system could potentially replace large, high-pressure NO cylinders, providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements, improving overall safety by eliminating NO2 purging steps, and offering other operational benefits.

LungFit can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g., COVID-19, bronchiolitis) and chronic, refractory lung infections in the home setting (e.g., NTM). With the elimination of cylinders, Beyond Air intends to offer NO treatment in the home setting.

*Beyond Air's LungFit PH is approved for commercial use in the United States, European Union, and many other countries around the world. Beyond Air's other LungFit systems are not approved for commercial use and are for investigational use only. Beyond Air is not suggesting NO use over 80 ppm or use at home.

Forward Looking Statements
This press release contains “forward-looking statements” concerning the potential safety and efficacy of inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and the potential impact on patients and anticipated benefits associated with inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate. Forward-looking statements include statements about expectations, beliefs, or intentions regarding product offerings, business, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “appears,” “expects,” “plans,” “anticipates,” “believes” “expects,” “intends,” “looks,” “projects,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for our product candidates; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; the ability to fund and the results of further pre-clinical studies and clinical trials of our product candidates; obtaining, maintaining and protecting intellectual property utilized by products; obtaining regulatory approval for products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the “Risk Factors” section of Beyond Air’s most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air’s website. Beyond Air and Beyond Cancer undertake no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law.

CONTACTS:
Investor Relations contacts

Corey Davis, Ph.D.
LifeSci Advisors, LLC
Cdavis@lifesciadvisors.com
(212) 915-2577

FAQ

What did Beyond Air (XAIR) say about the Feb 20, 2026 review on high‑dose iNO?

Beyond Air said the Feb 20, 2026 review reinforces interest in high‑dose iNO as an antimicrobial. According to the company, the paper synthesizes clinical and mechanistic data from 27 studies and may accelerate clinical development for pulmonary infections.

How many studies did the independent 2026 review analyze about high‑dose iNO?

The review synthesized evidence from 27 clinical and mechanistic studies. According to the company, those studies include early‑phase trials in pneumonia, COVID‑19, bronchiolitis, and nontuberculous mycobacteria, across in‑hospital and at‑home settings.

What potential antimicrobial effects of high‑dose iNO did the review highlight for investors in XAIR?

The review highlights direct microbial killing, biofilm disruption, antiviral effects, inflammation reduction, and improved mucociliary clearance. According to the company, these multimodal effects support further clinical evaluation in several pulmonary indications.

Does the review or Beyond Air claim high‑dose iNO is FDA‑approved for antimicrobial use?

No; the review discusses iNO delivered well above the FDA‑approved 20 ppm for vasodilation but does not indicate regulatory approval for antimicrobial indications. According to the company, further clinical development and regulatory work are needed.

Which respiratory conditions did Beyond Air cite as promising for high‑dose iNO development (XAIR)?

Beyond Air cited nontuberculous mycobacteria, bronchiolitis, community‑acquired and ventilator‑associated pneumonia, COVID‑19, post‑viral fibrosis, and immunocompromised patients. According to the company, the review outlines a roadmap prioritizing these pulmonary indications.